Royalty income enabled Genmab A/S to achieve a 51% increase in revenue in the first quarter of 2020 to DKK 892 million (€118.2 million), enabling the company to increase spending on its oncology pipeline which features two bispecific antibodies. The royalty income came from sales of Darzalex, a Genmab antibody developed by Janssen Biotech Inc which has been approved in the US for eight multiple myeloma indications.
